← Markets

Cryoport, Inc.

CYRX · NASDAQ

Market closed$16.51$0.020000 (+0.12%)After hours $16.91 · +2.42%

Chart data is refreshing.

Key statistics

Previous close$16.51
Open$16.29
Day high$16.89
Day low$16.16
52-week high$16.89
52-week low$6.69
Market cap832.14M
Volume702.12K
Average volume810.56K
P/E ratio-18.14
Forward P/E—
EPS-0.91
Dividend yield0.00%

Market context

Why it moved

CYRX edged slightly higher in quiet trading with no major company-specific news driving the move, suggesting the modest gain reflects routine market fluctuations and steady investor sentiment toward the cold chain logistics sector.

InstagramMoomooInstagramInstagramTiktok

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026Cryoport closed modestly lower, pulling back slightly after hitting a fresh 52-week high of $16.83 the prior session — a remarkable run given shares traded near $6.69 at their 52-week low. The stock remains well above its 200-day moving average of ~$11.25, underpinned by a consensus Moderate Buy rating and recent price target hikes from Needham, BTIG, and Craig Hallum (to $20). Investors are balancing the bullish momentum against notable insider selling, including the CFO offloading ~169K shares in June, and a Q1 EPS miss even as revenue topped expectations.

-0.4828

July 15, 2026Cryoport shares closed up roughly 2.3%, benefiting from a broader market rebound after June CPI came in softer than expected at 3.5%, easing rate-hike fears. Analyst sentiment remains constructive—Craig Hallum raised its price target to $20 in early June and BTIG lifted its target to $17, both maintaining Buy ratings—while the stock trades above its consensus target of $15.11. Notable insider selling by CFO Robert Stefanovich (169K shares at $16.27) and insider Edward Zecchini (33K shares) has drawn some scrutiny, though the company beat Q1 revenue estimates at $47.8M vs. $44.9M expected.

2.2915

July 14, 2026Cryoport closed down nearly 3% amid a broad market selloff driven by renewed U.S.-Iran tensions and a chip stock rout, though shares are recovering modestly in after-hours trade. Investor sentiment around the life sciences cold-chain logistics company is shaped by notable insider selling — the CFO offloaded over 169,000 shares in June — alongside a consensus 'Moderate Buy' rating with analysts at Needham, Craig-Hallum, and BTIG having recently raised price targets to a range of $15–$20, reflecting optimism around Cryoport's role in cell and gene therapy logistics.

-2.8448

July 11, 2026Cryoport shares gained nearly 3%, outperforming the broader industrials sector (XLI essentially flat) as the stock extended its run above the 200-day moving average — a technical milestone crossed just the prior session. The advance comes amid constructive analyst sentiment, with eight Buy ratings and recent price target hikes from Needham (to $15) and BTIG (to $17), supporting investor confidence in Cryoport's niche role as a temperature-controlled logistics provider for cell and gene therapies. The stock continued trading higher in after-hours, adding roughly 2% to reach $16.49, even as notable insider selling over the past 90 days remains a watchpoint for investors.

2.8626

July 9, 2026Cryoport shares rose on July 9 after crossing above their 200-day moving average for the first time, a technically significant milestone that drew investor attention. The breakout comes amid constructive analyst sentiment — eight analysts rate the stock a Buy — and recent price target hikes from Needham (to $15.00) and BTIG (to $17.00), with the consensus now at $15.11. Investor focus remains on Cryoport's specialized role in temperature-controlled logistics for cell and gene therapies, a niche that benefits from steady biotech pipeline growth, even as notable insider selling over the past 90 days warrants monitoring.

3.0144

June 30, 2026Cryoport fell sharply on the final trading day of the first half, weighed down by a wave of Russell index removals — the company was dropped from the Russell 2000, Russell 2500, and Russell Small Cap Composite Growth benchmarks over June 28–29. These index exits typically trigger forced selling from passive funds tracking those benchmarks, adding technical selling pressure. Despite the near-term headwind, the company raised full-year 2026 revenue guidance in May and Needham lifted its price target to $15, while a new partnership with Verismo Therapeutics to support KIR-CAR T cell therapy programs underscores continued momentum in its biopharma cold-chain logistics business.

-3.5627

June 30, 2026Cryoport gained nearly 2% on Monday, approaching its 52-week high, as the broader market rallied on news that the U.S. and Iran agreed to halt tit-for-tat strikes in the Strait of Hormuz, easing geopolitical tensions that had rattled markets last week. The session also brought notable index reshuffling news, with Cryoport dropped from multiple Russell growth benchmarks — including the Russell 2000, Russell 2500, and Russell Small Cap Comp Growth indexes — a development that could trigger passive fund selling pressure. Analyst sentiment remains constructive, however, with Craig-Hallum raising its price target to $20 in early June, and Cryoport's Q1 2026 results delivering raised full-year revenue guidance, while its IntegriCell unit recently secured a new partnership with Verismo Therapeutics.

1.75

June 26, 2026Cryoport shares gained over 2% as the company announced its IntegriCell® cryopreservation services were selected by Verismo Therapeutics to support two Phase 1 KIR-CAR T cell therapy programs—SynKIR-110 for solid tumors and SynKIR-310 for B-cell lymphomas. The deal reinforces Cryoport's growing footprint in cell and gene therapy supply chains, complementing recent analyst price target upgrades from KeyBanc, Needham, and BTIG following a strong Q1 beat where revenue rose 16.5% year-over-year to $47.8M and full-year 2026 guidance was raised.

2.3196

ad-hoc-news.de · July 19, 2026Cryoport stock trades steady as revenue grows and losses narrowMoomoo · July 16, 2026Craig-Hallum Maintains Cryoport(CYRX.US) With Buy RatingAd Hoc News · July 9, 2026CYRX stock stays supported by cold chain demand and biotech logistics growthPR Newswire · June 25, 2026Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy ProgramsStock Titan · June 9, 2026Cryoport (NASDAQ: CYRX) investors approve directors, pay and expanded equity planInvesting.com · May 5, 2026Needham raises CryoPort stock price target to $15 on revenue beatPR Newswire · May 4, 2026Cryoport Reports First Quarter 2026 Financial ResultsPR Newswire · March 3, 2026Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results
Mt Newswire · June 25, 2026CryoPort to Provide IntegriCell Cryopreservation Services for Verismo's Development Programs
Benzinga · June 25, 2026Cryoport’s IntegriCell Cryopreservation Services Selected By Verismo Therapeutics To Support SynKIR-110 And SynKIR-310 Multi-Chain KIR-CAR Programs
Mt Newswire · June 9, 2026Cryoport Insider Sold Shares Worth $2,756,984, According to a Recent SEC Filing
Benzinga · June 3, 2026Craig-Hallum Maintains Buy on CryoPort, Raises Price Target to $20
Benzinga · May 20, 2026Keybanc Maintains Overweight on CryoPort, Raises Price Target to $17
Benzinga · May 5, 2026Guggenheim Maintains Buy on CryoPort, Raises Price Target to $12
Mt Newswire · May 5, 2026Needham Raises Price Target on CryoPort to $15 From $13, Keeps Buy Rating
Benzinga · May 5, 2026Needham Maintains Buy on CryoPort, Raises Price Target to $15

Peers

S&P 500SPX · $7,457.69-1.01%BioLife Solutions, Inc.BLFS · $29.50-2.51%Thermo Fisher Scientific Inc.TMO · $531.03-2.24%United Parcel Service, Inc.UPS · $117.72+0.46%FedEx CorporationFDX · $314.00-1.32%Expeditors International of Washington, Inc.EXPD · $183.30+0.74%C.H. Robinson Worldwide, Inc.CHRW · $208.50+1.34%GXO Logistics, Inc.GXO · $54.01-0.99%Zebra Technologies CorporationZBRA · $267.66+0.99%Xylem Inc.XYL · $123.73-1.25%Digi International Inc.DGII · $63.92+0.11%Chart Industries, Inc.GTLS · $209.900.00%